These genes may potentially represent novel targets for personalized breast and ovarian cancer therapy, since their targeting should only inhibit proliferation of PARP10-overexpressing tumor cells, but should not affect the survival of normal tissues. This evidence concerns the gene PARP10 and neoplasm.